Peter Wehrwein

Articles

Prime Therapeutics Completes $1.35B Deal to Acquire Magellan Rx

December 06, 2022

Article

Magellan Rx's businesses includes a 1.7-million member PBM. The deal is struck amid a long-time trend toward consolidation in the pharmacy benefit management industry.

COVID-19 Associated With Decreased Sperm Concentration, Study Finds

December 02, 2022

Article

Evidence that COVID-19 might affect male fertility is accumulating, although it is an incomplete picture and there is no final word on the subject. This study found a possible effect on concentration but not on sperm motility or morphology.

COVID-19 Pandemic Caused Only a Dip in HIV Prevention, Care Services

December 01, 2022

Article

Results reported by CDC researchers show a sharp drop-off in HIV prevention and care services, such as preexposure prophylaxis prescriptions, in the second quarter of 2020 but then a rebound in third quarter.

Demand Up, Supply Down = Adderall Shortage

December 01, 2022

Article

Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.

Talking PIE, the Act, Before Thanksgiving

November 23, 2022

Article

AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.

FDA Approves Hemgenix, $3.5 million Gene Therapy for Hemophilia B

November 23, 2022

Article

Payers are bracing themselves for more ultra-expensive gene therapies.